Literature DB >> 19507258

Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG).

Audrey E Hendricks1, Jeanne C Latourelle, Kathryn L Lunetta, L Adrienne Cupples, Vanessa Wheeler, Marcy E MacDonald, James F Gusella, Richard H Myers.   

Abstract

Huntington disease (HD) is a dominantly transmitted neurodegenerative disorder that arises from expansion of a CAG trinucleotide repeat on chromosome 4p16.3. CAG repeat allele lengths are defined as fully penetrant at >or=40, reduced penetrance at 36-39, high normal at 27-35, and normal at <or=26. Fathers, but not mothers, with high normal alleles are at risk of transmitting potentially penetrant HD alleles (>or=36) to offspring. We estimated the conditional probability of an offspring inheriting an expanded penetrant allele given a father with a high normal allele by applying probability definitions and rules to estimates of HD incidence, paternal birth rate, frequency of de novo HD, and frequency of high normal alleles in the general population. The estimated probability that a male high normal allele carrier will have an offspring with an expanded penetrant allele ranges from 1/6,241 to 1/951. These estimates may be useful in genetic counseling for male high normal allele carriers.

Entities:  

Mesh:

Year:  2009        PMID: 19507258      PMCID: PMC2724761          DOI: 10.1002/ajmg.a.32901

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  24 in total

1.  New problems in testing for Huntington's disease: the issue of intermediate and reduced penetrance alleles.

Authors:  A Maat-Kievit; M Losekoot; H Van Den Boer-Van Den Berg; G J Van Ommen; M Niermeijer; M Breuning; A Tibben
Journal:  J Med Genet       Date:  2001-04       Impact factor: 6.318

2.  Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

Authors:  N E Maher; L I Golbe; A M Lazzarini; M H Mark; L J Currie; G F Wooten; M Saint-Hilaire; J B Wilk; J Volcjak; J E Maher; R G Feldman; M Guttman; M Lew; C H Waters; S Schuman; O Suchowersky; A L Lafontaine; N Labelle; P Vieregge; P P Pramstaller; C Klein; J Hubble; C Reider; J Growdon; R Watts; E Montgomery; K Baker; C Singer; M Stacy; R H Myers
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

3.  The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms.

Authors:  David R Gagnon; Mark E Glickman; Richard H Myers; L Adrienne Cupples
Journal:  Stat Med       Date:  2003-10-30       Impact factor: 2.373

4.  De novo expansion of a (CAG)n repeat in sporadic Huntington's disease.

Authors:  R H Myers; M E MacDonald; W J Koroshetz; M P Duyao; C M Ambrose; S A Taylor; G Barnes; J Srinidhi; C S Lin; W L Whaley
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

5.  Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects.

Authors:  Y P Goldberg; B Kremer; S E Andrew; J Theilmann; R K Graham; F Squitieri; H Telenius; S Adam; A Sajoo; E Starr
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

6.  A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats.

Authors:  B Kremer; P Goldberg; S E Andrew; J Theilmann; H Telenius; J Zeisler; F Squitieri; B Lin; A Bassett; E Almqvist
Journal:  N Engl J Med       Date:  1994-05-19       Impact factor: 91.245

7.  Trinucleotide repeat length instability and age of onset in Huntington's disease.

Authors:  M Duyao; C Ambrose; R Myers; A Novelletto; F Persichetti; M Frontali; S Folstein; C Ross; M Franz; M Abbott
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

8.  Technical standards and guidelines for Huntington disease testing.

Authors:  Nicholas T Potter; Elaine B Spector; Thomas W Prior
Journal:  Genet Med       Date:  2004 Jan-Feb       Impact factor: 8.822

9.  Estimation of morbid risk and age at onset with missing information.

Authors:  L A Cupples; N Risch; L A Farrer; R H Myers
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

10.  Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.

Authors:  D Brocklebank; J Gayán; J M Andresen; S A Roberts; A B Young; S R Snodgrass; J B Penney; M A Ramos-Arroyo; J J Cha; H D Rosas; S M Hersch; A Feigin; S S Cherny; N S Wexler; D E Housman; L R Cardon
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-04-05       Impact factor: 3.568

View more
  19 in total

1.  C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts.

Authors:  Carol Dobson-Stone; Marianne Hallupp; Lauren Bartley; Claire E Shepherd; Glenda M Halliday; Peter R Schofield; John R Hodges; John B J Kwok
Journal:  Neurology       Date:  2012-08-08       Impact factor: 9.910

2.  Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1.

Authors:  Gwen E Owens; Danielle M New; Anthony P West; Pamela J Bjorkman
Journal:  J Mol Biol       Date:  2015-06-03       Impact factor: 5.469

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

4.  HD CAG-correlated gene expression changes support a simple dominant gain of function.

Authors:  Jessie C Jacobsen; Gillian C Gregory; Juliana M Woda; Morgan N Thompson; Kathryn R Coser; Vidya Murthy; Isaac S Kohane; James F Gusella; Ihn Sik Seong; Marcy E MacDonald; Toshi Shioda; Jong-Min Lee
Journal:  Hum Mol Genet       Date:  2011-05-02       Impact factor: 6.150

Review 5.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 6.  Therapeutic approaches to preventing cell death in Huntington disease.

Authors:  Anna Kaplan; Brent R Stockwell
Journal:  Prog Neurobiol       Date:  2012-08-28       Impact factor: 11.685

7.  Dominant effects of the Huntington's disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategy.

Authors:  Jong-Min Lee; Ekaterina I Galkina; Rachel M Levantovsky; Elisa Fossale; Mary Anne Anderson; Tammy Gillis; Jayalakshmi Srinidhi Mysore; Kathryn R Coser; Toshi Shioda; Bin Zhang; Matthew D Furia; Jonathan Derry; Isaac S Kohane; Ihn Sik Seong; Vanessa C Wheeler; James F Gusella; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2013-04-16       Impact factor: 6.150

8.  Evidence for penetrance in patients without a family history of disease: a systematic review.

Authors:  Heather Turner; Leigh Jackson
Journal:  Eur J Hum Genet       Date:  2020-01-14       Impact factor: 4.246

9.  Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin hypomorphs.

Authors:  Roy Jung; Yejin Lee; Douglas Barker; Kevin Correia; Baehyun Shin; Jacob Loupe; Ryan L Collins; Diane Lucente; Jayla Ruliera; Tammy Gillis; Jayalakshmi S Mysore; Lance Rodan; Jonathan Picker; Jong-Min Lee; David Howland; Ramee Lee; Seung Kwak; Marcy E MacDonald; James F Gusella; Ihn Sik Seong
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

10.  Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT.

Authors:  Ainhi D Ha; Christopher A Beck; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.